Thrombotic safety of rofecoxib v placebo for colorectal adenomas at 3 years*
| Outcomes | Rofecoxib | Placebo | RRI (95% CI) | NNH (CI) | ||
|---|---|---|---|---|---|---|
| Event rates | Patient years at risk | Event rates | Patient years at risk | |||
| *APTC = Antiplatelet Trialists’ Collaboration. Other abbreviations defined in glossary; RRI, NNH, and CI calculated from relative risks in article. | ||||||
| Thrombotic events | 3.6% | 3059 | 2.0% | 3327 | 92% (19 to 211) | 55 (24 to 264) |
| APTC combined endpoint | 2.6% | 3070 | 1.4% | 3334 | 106% (16 to 264) | 68 (28 to 447) |